PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Negative EBIT growth while Biotechnology median is -0.96%. Seth Klarman would check if external or internal factors caused the decline.
-14.34%
Negative operating income growth while Biotechnology median is -1.17%. Seth Klarman would check if structural or cyclical issues are at play.
-20.40%
Negative net income growth while Biotechnology median is -3.99%. Seth Klarman would investigate factors dragging net income down.
-19.61%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-20.61%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.76%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Negative OCF growth while Biotechnology median is -4.60%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-26.42%
Negative FCF growth while Biotechnology median is -3.39%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-21838.35%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
2.60%
3Y OCF/share growth of 2.60% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-1109485.80%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-20425.82%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
78.21%
3Y net income/share CAGR of 78.21% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
41985.76%
Equity/share CAGR of 41985.76% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
3459.24%
5Y equity/share CAGR of 3459.24% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
143.15%
3Y equity/share CAGR of 143.15% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-29.04%
Negative BV/share change while Biotechnology median is -3.98%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth of 15.43% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
12.93%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.